文献速递免疫规划

IL-33增强HIV-1 DNA与蛋白疫苗抗体应答的动力学与质量

IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.
PubMed 文献 · Vaccine · 2019-03-27

研究在小鼠中评估DNA初免阶段加入MPLA或IL-33对HIV-1 Env疫苗体液应答的影响。IL-33使首次免疫后即产生高滴度gp120特异性血浆IgG,并提高抗体亲和力、广度与持久性,同时促进IgM应答和B-1b B细胞扩增。

要点

  • DNA初免阶段加入IL-33可加速gp120特异性IgG产生。
  • IL-33提高抗体亲和力、广度与持久性。
  • IL-33促进IgM应答及腹腔和脾脏B-1b B细胞扩增。

核心结论

  • DNA初免时加入外源性IL-33可定性改变HIV-1 Env特异性体液应答,改善潜在保护性抗体的动力学与广度。

研究设计与样本

  • 使用VC10014 DNA与蛋白疫苗(HIV-1 Env gp160质粒和来源于B亚型感染者的三聚体gp140蛋白)在小鼠中评估DNA初免阶段给予MPLA和IL-33对体液应答的影响。

主要发现

  • gp160 DNA初免阶段加入IL-33后,首次免疫即产生高滴度gp120特异性血浆IgG。
  • 经DNA与蛋白共免疫(明矾佐剂)后,IL-33处理小鼠的血浆IgG抗体亲和力、广度和持久性高于MPLA及仅明矾处理小鼠。
  • IL-33与显著的IgM Env特异性应答及腹腔和脾脏B-1b B细胞扩增相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Induction of a sustained and broad antibody (Ab) response is a major goal in developing a protective HIV-1 vaccine. DNA priming alone shows reduced levels of immunogenicity; however, when combined with protein boosting is an attractive vaccination strategy for induction of humoral responses. Using the VC10014 DNA and protein-based vaccine consisting of HIV-1 envelope (Env) gp160 plasmids and trimeric gp140 proteins derived from an HIV-1 clade B infected subject who developed broadly neutralizing serum Abs, and which has been previously demonstrated to induce Tier 2 heterologous neutralizing Abs in rhesus macaques, we evaluated whether MPLA and IL-33 when administered during the DNA priming phase enhances the humoral response in mice. The addition of IL-33 during the gp160 DNA priming phase resulted in high titer gp120-specific plasma IgG after the first immunization. The IL-33 treated mice had higher plasma IgG Ab avidity, breadth, and durability after DNA and protein co-immunization with alum adjuvant as compared to MPLA and alum only treated mice. IL-33 was also associated with a significant IgM Env-specific response and expansion of peritoneal and splenic B-1b B cells. These results indicate that DNA priming in the presence of exogenous IL-33 qualitatively alters the HIV-1 Env-specific humoral response, improving the kinetics and breadth of potentially protective Ab.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sarkar S, Piepenbrink MS, Basu M, et al. IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine. Vaccine. 2019. PMID: 30926296. doi:10.1016/j.vaccine.2019.03.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。